Fluence Energy Inc. Class A Common Stock vs Heron Therapeutics Inc — how do they compare? Fluence Energy Inc. Class A Common Stock trades at $6.18 (market cap $969.93M), while Heron Therapeutics Inc trades at $0.37 (market cap $74.18M). The key difference: Fluence Energy Inc. Class A Common Stock is far larger — about 13.1× Heron Therapeutics Inc's market cap, and Fluence Energy Inc. Class A Common Stock is more actively traded (7,001,648 versus 1,857,401). Which is the better fit depends on your goals — on Pluang, investors hold Fluence Energy Inc. Class A Common Stock for 0 Days and Heron Therapeutics Inc for 36 Days on average.
| FLNC | HRTX | |
|---|---|---|
Market Cap | $969.93M | $74.18M |
Volume | 7,001,648 | 1,857,401 |
Sector | Utilities | Health |
52-Week High | $32.23 | $1.49 |
52-Week Low | $6.21 | $0.27 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $1.02B | $180.92M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HRTX trades at $0.3906, down 6.02% today, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates. Despite a high gross margin of 70.07%, it posted a net loss of -$20.20 million in 2025. Analyst consensus is strongly positive with 17 buy ratings. Recent news highlights earnings results and competitive comparisons.
The outlook remains speculative given persistent losses and negative ROE, but strong analyst support and improving cash flow trends offer potential upside. Key risks include profitability challenges and revenue volatility. Investors should weigh the bullish sentiment against fundamental weaknesses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Fluence Energy Inc. designs and delivers energy storage products, operational services, and asset optimization software for renewable-energy and storage applications worldwide.
Read more on FLNC →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →